Omeros Earnings Call: YARTEMLEA Fuels a New Phase

Omeros Corporation ((OMER)) has held its Q1 earnings call. Read on for the main highlights of the call.

Omeros Corporation’s latest earnings call struck an overall optimistic tone, with management highlighting the rapid approval and early launch success of YARTEMLEA, strengthened by a sizable non‑dilutive cash infusion from Novo Nordisk and a solid balance sheet. While they acknowledged ongoing losses, earnings volatility from derivative accounting, and the early stage of commercial adoption, executives stressed that regulatory wins, cash flows, and pipeline momentum outweigh near‑term financial noise.

YARTEMLEA Wins First-to-Market FDA Approval

YARTEMLEA, a MASP‑2 inhibitor, secured FDA approval as the first and only treatment for TA‑TMA and the first approved inhibitor of the lectin complement pathway, cementing a significant competitive edge. The drug launched in mid‑January, with initial shipments and sales shortly after, positioning Omeros as a pioneer in this high‑need niche market.

Strong Early Commercial Uptake in Transplant Centers

Early commercial performance for YARTEMLEA was described as strong, with Q1 2026 gross revenue at $11.1 million and net revenue at $9.9 million, implying gross‑to‑net adjustments of about 11%. By March 31, 30 unique accounts had ordered the drug, including six of the top 10 and 24 of the top 80 transplant centers, signaling rapid penetration of key institutions.

YARTEMLEA Turns Cash Flow Positive in First Quarter

Despite launching mid‑January, YARTEMLEA became cash flow positive in the first quarter, reflecting efficient pricing, demand, and distribution dynamics. Management emphasized that this trajectory supports their expectation that YARTEMLEA will drive company‑wide positive cash flow within roughly 18 months.

Novo Nordisk Deal Delivers Major Non-Dilutive Capital

Omeros secured $240 million upfront from Novo Nordisk for zaltenibart, with eligibility for $100 million in near‑term milestones and a total deal value up to $2.1 billion plus high single‑digit to high‑teen royalties. This large, non‑dilutive capital injection significantly strengthens funding for operations, the YARTEMLEA launch, and broader R&D efforts without issuing new equity.

Cash Reserves and Share Buybacks Support Investor Confidence

The company ended Q1 with $135.3 million in cash and investments after retiring its remaining 2026 notes, demonstrating a stronger balance sheet. Omeros also repurchased and retired about 360,000 shares at an average price of $11.70, spending roughly $4.2 million in a signal of confidence in its valuation and future prospects.

Reimbursement Tailwinds: J-Code and Potential NTAP

Access and reimbursement prospects improved as CMS assigned a permanent J‑code for YARTEMLEA effective July 1, aimed at simplifying hospital billing. In parallel, CMS proposed a New Technology Add‑On Payment for YARTEMLEA, with a final decision expected in August and potential effectiveness from October 1, which would enhance inpatient reimbursement and facilitate broader clinical adoption.

International Expansion and Label Growth Prospects

Beyond the U.S., Omeros is pursuing a marketing authorization for YARTEMLEA with the EMA, with a decision anticipated around midyear, laying groundwork for European revenues. Management is also evaluating ex‑U.S. partnerships and additional indications, including ARDS, sickle cell disease, acute kidney injury, and transplant‑related complications, which could materially expand the drug’s addressable market.

Diversified Pipeline Gains Validation and Momentum

The broader pipeline is advancing, with a Phase II‑ready long‑acting MASP‑2 antibody (OMS1029) and an oral MASP‑2 small‑molecule program entering IND‑enabling stages, extending the complement franchise. OMS527 (PDE7) is fully funded by NIDA with an inpatient human study targeted by year‑end, while T‑CAT and OncotoX‑AML programs have shown compelling preclinical data and gained scientific recognition, with first‑in‑human AML studies planned for late 2027.

Adjusted Losses Highlight Near-Term Profitability Pressure

On a non‑GAAP basis excluding noncash derivative movements, Omeros recorded an adjusted net loss of $17.1 million in Q1 2026, or $0.24 per share, reflecting ongoing investment in commercialization and R&D. Management signaled that operating expenses, particularly sales and marketing tied to the YARTEMLEA rollout, will edge higher in Q2, keeping near‑term profitability under pressure.

Derivative Accounting Drives Net Income Volatility

Reported net income reached $56.1 million, or $0.78 per share, but this headline result was dominated by a $73.1 million noncash mark‑to‑market gain on convertible note derivatives. Management cautioned that these remeasurements, driven primarily by stock price and market inputs, will continue to create significant quarter‑to‑quarter earnings volatility unrelated to core business performance.

Stock Decline and Remaining Debt Add Complexity

The company’s stock price fell from $17.18 at year‑end 2025 to $10.56 at March 31, a roughly 38.5% drop that contributed to the noncash derivative gain in Q1 and could reverse if shares recover. Omeros still carries $70.8 million in principal on unsecured 2029 convertible notes, and Q1 interest expense totaled $5.9 million, with expectations for about $7.1 million in Q2, creating a continuing drag on earnings.

Early Launch Stage and Gross-to-Net Risks

Management offered limited disclosure on patient‑level metrics, noting only that 30 accounts had ordered by quarter‑end, underlining that YARTEMLEA is still in an early commercialization phase. They also warned that gross‑to‑net adjustments, now around the low teens, could rise as 340B participation increases, potentially pressuring net revenue per unit even as volumes grow.

Forward-Looking Guidance Underlines Cash Flow and Milestones

Guidance remains qualitative on revenue, but Omeros expects slightly higher Q2 operating expenses, interest expense around $7.1 million, and beneficial discontinued‑operations income of roughly $5–6 million alongside higher interest income. Management reiterated aims for YARTEMLEA to deliver company‑wide positive cash flow within 18 months, highlighted upcoming reimbursement decisions, an EMA ruling, the OMS527 inpatient study by year‑end, and a first‑in‑human OncotoX‑AML study scheduled for late 2027.

Omeros’ earnings call presented a story of a company transitioning from development to commercialization, with YARTEMLEA already providing meaningful revenues, cash flow, and strategic leverage. While adjusted losses, debt, and accounting‑driven volatility remain, the combination of regulatory wins, non‑dilutive capital, and a broadening pipeline offered investors a clear growth narrative anchored by a first‑in‑class therapy.